Senti Biosciences, Inc.
SNTISenti Biosciences, Inc. in brief
Senti Biosciences, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $19 M on 30 October 2026, which makes it the 24,528th largest listed company in the world and the 4,167th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $61 M. It employs about 39 people and Timothy K. Lu is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol SNTI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Senti Biosciences, Inc.
We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Using gene circuits, our product candidates are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration.
From the company's annual report filed with the US SEC: read the report
Senti Biosciences, Inc. timeline
- 2021
- 🔔· approximateInitial public offering on Nasdaq
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 💰Record revenue of $4 millionFY2022, the highest of the 4 years on record.
- ✎Renamed Senti Biosciences, Inc.\Formerly Dynamics Special Purpose Corp..
- 2026
- ✎Renamed Senti Biosciences Holdings, Inc.Formerly Senti Biosciences, Inc.\.
Events of Senti Biosciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,669 (Dec 2022) · #4,882 (Jul 2023) · #4,274 (Jan 2024) · #2,286 (Mar 2026) · #3,998 (Aug 2026) · #4,287 (Oct 2026) · #4,170 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 943.0×
- Price / book
- 3.4×
- Free cash flow yield
- -231.4%
- Net margin
- -307200.0%
- Operating margin
- -343900.0%
- Return on equity
- -1099.1%
- Liabilities / assets
- 89.1%
- Revenue growth
- -99.2%
- R&D / revenue
- 187950.0%
- Revenue per employee
- $1 K
- Profit per employee
- $-1.6 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | — | $-69M | $-61M | -307200.0% |
| Dec 2024 | — | — | $-61M | $-53M | — |
| Dec 2023 | $3M | -40.3% | $-93M | $-71M | -2775.8% |
| Dec 2022 | $4M | +55.4% | $-62M | $-58M | -1356.9% |
| Dec 2021 | $3M | — | $-40M | $-55M | -2004.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-43M | $0M | $-44M | $-2.73 | — |
| Dec 2024 | $-41M | $0M | $-41M | $-12.03 | — |
| Dec 2023 | $-52M | $12M | $-64M | $-16.01 | — |
| Dec 2022 | $-35M | $41M | $-76M | $-2.23 | — |
| Dec 2021 | $-35M | $6M | $-40M | $-19.00 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $0M, net income $-13M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 10, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Oct 27, 20268-KCurrent reportDirectors or officers changed · Other events
- Oct 26, 20268-KCurrent reportMaterial agreement · Agreement ended · Acquisition or disposal completed · Unregistered share sale
- Oct 15, 20268-KCurrent reportShareholder vote
- Oct 13, 20268-KCurrent reportOther events
- Sep 24, 20268-KCurrent reportDirectors or officers changed
- Sep 4, 20268-KCurrent reportMaterial agreement · New financial obligation
- Sep 2, 20268-KCurrent reportMaterial agreement · Listing notice
- Aug 20, 20268-KCurrent reportMaterial agreement · New financial obligation
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 15, 20268-KCurrent reportMaterial agreement · Results of operations · Change in control · Regulation FD disclosure · Other events
- May 26, 20268-KCurrent reportMaterial agreement · New financial obligation
Official filings of Senti Biosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-69 M
- Net income
- $-61 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $51 M
- Total liabilities
- $46 M
- Total equity
- $6 M
As of December-2025
Top 22 institutional investors in Senti Biosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 537,504 | 0 (0.00%) | 1.73% | $0 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 176,602 | -10,463 (-5.59%) | 0.57% | $0 M | Nov 6, 2026 |
| 3 | Two Sigma Securities, LLC | 153,480 | New | 0.49% | $0 M | Nov 16, 2026 |
| 4 | GTS Securities LLC | 110,000 | New | 0.35% | $0 M | Nov 16, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 91,193 | 0 (0.00%) | 0.29% | $0 M | Nov 13, 2026 |
| 6 | HRT Financial LP | 53,827 | New | 0.17% | $0 M | Nov 13, 2026 |
| 7 | Virtu Financial LLC | 47,271 | +24,476 (+107.37%) | 0.15% | $0 M | Nov 17, 2026 |
| 8 | Menlo Ventures Management, L.P. | 35,737 | 0 (0.00%) | 0.11% | $0 M | Nov 6, 2026 |
| 9 | Northern Trust Corp | 32,154 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 10 | Susquehanna International Group, LLP | 23,147 | New | 0.07% | $0 M | Nov 16, 2026 |
| 11 | UBS Group AG | 17,402 | +2,970 (+20.58%) | 0.06% | $0 M | Nov 10, 2026 |
| 12 | Citadel Advisors LLC | 16,365 | -90,735 (-84.72%) | 0.05% | $0 M | Nov 16, 2026 |
| 13 | XTX Topco Ltd | 14,885 | -8,725 (-36.95%) | 0.05% | $0 M | Nov 16, 2026 |
| 14 | State Street Corp | 10,010 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 15 | Nuveen, LLC | 9,819 | New | 0.03% | $0 M | Nov 10, 2026 |
| 16 | Tower Research Capital LLC (TRC) | 8,959 | +1,615 (+21.99%) | 0.03% | $0 M | Nov 16, 2026 |
| 17 | Royal Bank Of Canada | 4,015 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 18 | SBI Securities Co., Ltd. | 523 | +189 (+56.59%) | 0.00% | $0 M | Oct 22, 2026 |
| 19 | BlackRock, Inc. | 262 | -3,742 (-93.46%) | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Morgan Stanley | 160 | -9 (-5.33%) | 0.00% | $0 M | Nov 13, 2026 |
| 21 | Barclays PLC | 10 | -758 (-98.70%) | 0.00% | $0 M | Nov 6, 2026 |
| 22 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Senti Biosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 368,878 | $0 M | 1.2% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 168,626 | $0 M | 0.54% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 95,866 | $0 M | 0.31% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 24,798 | $0 M | 0.08% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 19,991 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 18,801 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Senti Biosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kanya RajangamPres. & Chief Med. & Dev. Off. | Shares withheld for tax | -19,953 | — | — | 54,890 | Form 4 |
| filed | Timothy K. LuCEO, Director | Shares withheld for tax | -157,312 | — | — | 482,271 | Form 4 |
| filed | Timothy K. LuCEO, Director | Shares withheld for tax | -80,666 | — | — | 639,583 | Form 4 |
| filed | Kanya RajangamPres. & Chief Med. & Dev. Off. | Shares withheld for tax | -10,757 | — | — | 74,843 | Form 4 |
| filed | Timothy K. LuCEO, Director | Shares withheld for tax | -4,191 | — | — | 720,249 | Form 4 |
| filed | Kanya RajangamPres. & Chief Med. & Dev. Off. | Shares withheld for tax | -1,384 | — | — | 85,600 | Form 4 |
| filed | Celadon Partners SPV 2410% owner | Conversion | +9.78 M | — | — | 9.78 M | Form 4 |
| filed | Anthony A. Florence Jr.10% owner | Conversion | +3.33 M | — | — | 3.78 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Senti Biosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
Trading halts
- 2026-11-19 00:50 UTC, code T3, resumed 14:00 UTC
- 2026-07-15 11:25 UTC, code T3, resumed 12:00 UTC
- 2025-02-28 15:01 UTC, code LUDP, resumed 15:06 UTC
- 2025-02-28 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2025-02-28 14:41 UTC, code LUDP, resumed 14:46 UTC
Fails to deliver
- : 802,064 shares at $0.22
- : 792,173 shares at $0.22
- : 1.7 M shares at $0.19
- : 2.2 M shares at $0.18
- : 13,225 shares at $0.19
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Senti Biosciences, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.4×Price to book 3.4× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median943.0×Price to sales 943.0× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.73 vs -12.03Diluted EPS -2.73 in fiscal 2025 against -12.03 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$61 MNet income -$61 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-393.3%-393.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.67 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-13.77Z-score -13.77 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year389.2%Diluted shares up 389.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Senti Biosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 0.0—100% | 0−100%— | 2.6−40.2%100% | 4.3+55.2%100% | 2.8—100% | |
| Research and development | 38+9.4%170845% | 34+6.9%— | 32+14.2%1255% | 28r34+28.2%657% | 22—795% | |
| General and administrative | 26−0.8%118923% | 26−29.1%— | 37−2.7%1452% | 38r41+79.9%892% | 21—770% | |
| Operating expenses | 69+12.7%312732% | 61−35.9%— | 95+43.6%3721% | 66r75+53.6%1549% | 43—1565% | |
| Operating income | −69—−312632% | −61—— | −93—−3621% | −62r−71—−1449% | −40—−1465% | |
| Other non-operating income (expense) | 7.3−11.0%33368% | 8.2−11.5%— | 9.3−24.9%364% | 12—290% | −15—−539% | |
| Income tax | 0—0.0% | 0—— | — | — | — | |
| Income from continuing operations | −61—−279264% | −53—— | −83—−3257% | −50—−1159% | — | |
| Income from discontinued operations | — | 0−100%— | 12—482% | −8.5—−199% | — | |
| Net income attributable to shareholders | −61—−279264% | −53—— | −71—−2775% | −58—−1358% | −55—−2004% | |
| Earnings per share, basic | -2.73—— | -12.03—— | -16.01r-1.60—— | -2.23—— | -19.00—— | |
| Earnings per share, diluted | -2.73—— | -12.03—— | -16.01r-1.60—— | -2.23—— | -19.00—— | |
| Shares, weighted average (basic) | 22+389%— | 4.6+3.6%— | 4.4r44−83.0%— | 26+797%— | 2.9—— | |
| Shares, weighted average (diluted) | 22+389%— | 4.6+3.6%— | 4.4r44−83.0%— | 26+797%— | 2.9—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 16−66.0%32.1% | 48+34.4%49.3% | 36−37.7%30.1% | 58+2.8%31.9% | 56r0.9—57.9% | |
| Short-term investments | — | — | 0−100%0.0% | 41—22.6% | 0—0.0% | |
| Receivables | — | — | — | 0.6+29.6%0.3% | 0.5—0.5% | |
| Other current assets | 0−100%0.0% | 0.6+199%0.6% | 0.2+93.1%0.2% | 0.1−63.3%0.1% | 0.3—0.3% | |
| Current assets | 23−60.5%45.4% | 59−17.2%60.3% | 71−30.6%59.6% | 103+70.4%56.7% | 60r1.3—62.2% | |
| Property, plant and equipment | 13−39.5%25.2% | 21−16.0%21.8% | 25−50.7%21.2% | 51r56+315%28.4% | 12—12.8% | |
| Right-of-use (leased) assets | 12−17.4%22.5% | 14−14.3%14.3% | 16−11.6%13.6% | 18−11.1%10.2% | 21—21.4% | |
| Total assets | 51−47.6%100% | 98−18.1%100% | 119−33.9%100% | 181+87.0%100% | 97r231—100% | |
| Accounts payable | 2.9+102%5.7% | 1.5+16.3%1.5% | 1.3−8.8%1.0% | 1.4r2.3−73.6%0.8% | 5.2—5.4% | |
| Current liabilities | 14+6.3%27.3% | 13+3.7%13.4% | 13−29.8%10.6% | 18+24.1%10.0% | 15r3.3—15.0% | |
| Lease liabilities (non-current) | 24−18.4%46.0% | 29−13.9%29.5% | 34−4.5%28.1% | 35+67.3%19.4% | 21—21.7% | |
| Total liabilities | 46−3.1%89.1% | 47−10.4%48.1% | 53−1.8%44.0% | 54+47.4%29.6% | 36r10—37.6% | |
| Retained earnings | −359—−700% | −297—−304% | −244—−204% | −173—−95.8% | −115r−8.9—−119% | |
| Shareholders' equity | 5.6−78.2%10.9% | 26−61.7%26.2% | 67−47.4%56.0% | 127—70.4% | −111r−8.9—−115% | |
| Total liabilities and equity | 51−47.6%100% | 98−18.1%100% | 119−33.9%100% | 181+87.0%100% | 97r231—100% | |
| Shares outstanding | 31+539%— | 4.8+5.7%— | 4.6r46−89.6%— | 44+1382%— | 3.0—— | |
| Cash-flow statement | ||||||
| Share-based compensation | 5.7+225%25936% | 1.8−81.9%— | 9.7−41.0%378% | 16+614%382% | 2.3—83.1% | |
| Cash from operating activities | −43—−197473% | −41—— | −52—−2046% | −35—−814% | −35—−1254% | |
| Capital expenditure | −0.2—−891% | −0.0—— | −12—−470% | −41—−965% | −5.5—−201% | |
| Cash from investing activities | −0.2−641%−836% | 0.0−99.9%— | 30—1174% | −82—−1912% | −5.5—−201% | |
| Shares issued | — | 1.8+253%— | 0.5−29.7%20.0% | 0.7—17.0% | 0—0.0% | |
| Cash from financing activities | 12−78.1%53459% | 54+6797%— | 0.8−99.3%30.4% | 119+73.2%2766% | 68—2479% | |
| Change in cash | −32−358%−144850% | 12—— | −22−1370%−841% | 1.7−94.0%39.6% | 28—1023% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0.0—100% | 0.0—100% | — | — | 0—— | 0—— | 0*—— | 0−100%— | 0—— | 0—— | 0*—— | 0.3—100% | |
| Research and development | 31−12.3%— | 7.8−22.6%45688% | 5.3−43.1%33006% | 7.8*−0.2%— | 11+21.5%— | 10+9.6%— | 9.3+5.7%— | 7.8*−14.8%— | 8.7−4.8%— | 9.2—— | 8.8—— | 9.1*—— | 9.1—2690% | |
| General and administrative | 25−11.5%— | 6.7−0.4%39641% | 6.2−12.4%38956% | 5.8*−27.7%— | 6.4−2.0%— | 6.8+61.0%— | 7.1−5.4%— | 8.1r8.4*−13.1%— | 6.6r6.2−30.4%— | 4.2—— | 7.5—— | 9.3*—— | 9.4—2790% | |
| Operating expenses | 55−15.2%— | 15−13.6%85329% | 4.6−71.8%28950% | 19*+15.4%— | 17+11.4%— | 17+25.8%— | 16+0.6%— | 16*−13.5%— | 15−65.6%— | 13—— | 16—— | 19*—— | 44—13081% | |
| Operating income | −55—— | −14—−85229% | −4.6—−28850% | −19*—— | −17—— | −17—— | −16—— | −16*—— | −15—— | −13—— | −16—— | −19*—— | −44—−12981% | |
| Other non-operating income (expense) | 5.1−18.1%— | 1.7−15.8%10229% | 0.4−82.7%2469% | 4.2*−73.2%— | −1.2—— | 2.1−4.1%— | 2.3−45.5%— | 16*+155470%— | −14−288%— | 2.2—— | 4.2—— | 0.0*—— | 7.3—2148% | |
| Income tax | 0—— | 0—0.0% | 0—0.0% | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | — | 0—0.0% | |
| Income from continuing operations | — | −13—−75000% | −4.2—−26381% | — | — | −15—— | −14—— | −0.6*—— | −29—— | −11—— | −12—— | −83—— | −37—−10833% | |
| Income from discontinued operations | — | — | — | — | — | — | — | 0*−100%— | 0−100%— | 0—— | 0—— | 12—— | 22—6418% | |
| Net income attributable to shareholders | −50—— | −13—−75000% | −4.2—−26381% | −14*—— | −18—— | −15—— | −14—— | −0.6*—— | −29—— | −11—— | −12—— | −71—— | −15—−4415% | |
| Earnings per share, basic | — | -0.41—— | -0.14—— | — | -0.69—— | -0.56—— | -1.41—— | — | -6.31—— | -2.45—— | -2.65r-0.26—— | — | -3.36r-0.34—— | |
| Earnings per share, diluted | — | -0.41—— | -0.14—— | — | -0.69—— | -0.56—— | -1.41—— | — | -6.31—— | -2.45—— | -2.65r-0.26—— | — | -3.36r-0.34—— | |
| Shares, weighted average (basic) | 31+19.4%— | 31+19.4%— | 31+209%— | — | 26+473%— | 26+470%— | 10+119%— | — | 4.6+2.9%— | 4.6—— | 4.6r46—— | — | 4.4r44—— | |
| Shares, weighted average (diluted) | 31+19.4%— | 31+19.4%— | 31+209%— | — | 26+473%— | 26+470%— | 10+119%— | — | 4.6+2.9%— | 4.6—— | 4.6r46—— | — | 4.4r44—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.5—19.5% | 6.5−70.0%19.5% | 8.9−73.6%23.4% | 16−66.0%32.1% | 12+16.8%23.2% | 22+36.0%31.5% | 34+42.5%40.8% | 48+34.4%49.3% | 10−73.4%18.2% | 16—18.2% | 24—23.2% | 36—30.1% | 39—29.9% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | |
| Other current assets | 0.3—0.9% | 0.3—0.9% | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0—0.0% | 0.6+199%0.6% | 0.0−98.4%0.0% | 0.0—0.0% | 0—0.0% | 0.2—0.2% | 0.5—0.4% | |
| Current assets | 13—39.3% | 13−60.0%39.3% | 15−67.3%38.7% | 23−60.5%45.4% | 18+4.5%34.5% | 33−26.7%47.4% | 45−18.8%54.6% | 59−17.2%60.3% | 17−78.0%30.1% | 44—51.0% | 56—54.5% | 71—59.6% | 79—60.0% | |
| Property, plant and equipment | 11—34.5% | 11−41.6%34.5% | 12−41.1%31.6% | 13−39.5%25.2% | 19−15.9%35.5% | 20−15.7%28.6% | 21−15.7%24.8% | 21−16.0%21.8% | 22−15.9%38.5% | 23—26.8% | 24—23.8% | 25—21.2% | 26—20.1% | |
| Right-of-use (leased) assets | 7.2—21.9% | 7.2−43.6%21.9% | 7.8−41.7%20.4% | 12−17.4%22.5% | 12−15.3%23.3% | 13−16.1%18.7% | 13−15.1%16.2% | 14−14.3%14.3% | 14−15.0%25.1% | 15—17.6% | 16—15.5% | 16—13.6% | 17—12.9% | |
| Total assets | 33—100% | 33−51.7%100% | 38−53.8%100% | 51−47.6%100% | 53−8.7%100% | 69−21.1%100% | 83−19.0%100% | 98−18.1%100% | 58−56.2%100% | 87—100% | 102—100% | 119—100% | 132—100% | |
| Accounts payable | 2.2—6.8% | 2.2+120%6.8% | 1.1−32.5%2.8% | 2.9+102%5.7% | 1.8+123%3.4% | 1.0−13.6%1.5% | 1.6−4.0%1.9% | 1.5+16.3%1.5% | 0.8−60.2%1.4% | 1.2—1.4% | 1.6—1.6% | 1.3—1.0% | 2.0—1.5% | |
| Current liabilities | 16—47.6% | 16+57.9%47.6% | 14+33.0%37.3% | 14+6.3%27.3% | 12+32.7%22.8% | 10.0+10.1%14.6% | 11+11.6%13.0% | 13+3.7%13.4% | 9.1−10.4%15.7% | 9.1—10.4% | 9.6—9.4% | 13—10.6% | 10—7.7% | |
| Lease liabilities (non-current) | 13—38.5% | 13−51.6%38.5% | 13−52.1%34.6% | 24−18.4%46.0% | 25−17.1%47.4% | 26−15.9%38.4% | 28−14.8%33.4% | 29−13.9%29.5% | 30−13.0%52.2% | 31—36.0% | 32—31.8% | 34—28.1% | 35—26.3% | |
| Total liabilities | 37—110% | 37−16.8%110% | 36−20.6%93.3% | 46−3.1%89.1% | 45+6.8%84.6% | 44+2.6%64.0% | 45−2.5%54.3% | 47−10.4%48.1% | 42−14.5%72.3% | 43—49.2% | 46—45.1% | 53—44.0% | 49—37.1% | |
| Retained earnings | −376—−1134% | −376—−1134% | −363—−949% | −359—−700% | −344—−653% | −326—−476% | −311—−376% | −297—−304% | −297—−514% | −268—−308% | −256—−251% | −244—−204% | −226—−171% | |
| Shareholders' equity | −3.4—−10.3% | −3.4−114%−10.3% | 2.6−93.2%6.7% | 5.6−78.2%10.9% | 8.1−49.2%15.4% | 25−44.2%36.0% | 38−32.5%45.7% | 26−61.7%26.2% | 16−80.7%27.7% | 44—50.8% | 56—54.9% | 67—56.0% | 83—62.9% | |
| Total liabilities and equity | 33—100% | 33−51.7%100% | 38−53.8%100% | 51−47.6%100% | 53−8.7%100% | 69−21.1%100% | 83−19.0%100% | 98−18.1%100% | 58−56.2%100% | 87—100% | 102—100% | 119—100% | 132—100% | |
| Shares outstanding | 31—— | 31+19.1%— | 31+19.8%— | 31+539%— | 26+473%— | 26+472%— | 26−43.1%— | 4.8+5.7%— | 4.6−89.7%— | 4.6—— | 46—— | 4.6r46—— | 44—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5.3+33.4%— | 1.0−31.3%6165% | 1.3+9.2%8219% | 1.4*+136%— | 1.6+132%— | 1.5—— | 1.2−4.3%— | 0.6*−70.7%— | 0.7+63.3%— | −0.8—— | 1.3—— | 2.1*—— | 0.4r2.5—121% | |
| Cash from operating activities | −38—— | −14*—−83818% | −7.5—−46756% | −6.9*—— | −9.4*—— | −13*—— | −14—— | −14*—— | −7.9*—— | −8.3*—— | −12—— | −7.0*—— | −15*—−4550% | |
| Capital expenditure | — | — | — | 0*—— | 0*—— | −0.2*—— | 0—— | −0.0*—— | 0*—— | 0*—— | −0.0—— | −0.0*—— | −1.9*—−550% | |
| Cash from investing activities | 0.1—— | 0*—0.0% | 0.1—713% | 0*—— | 0*−100%— | −0.2*—— | 0—— | −0.0*−111%— | 0.1*−99.7%— | 0*—— | −0.0—— | 0.1*—— | 21*—6255% | |
| Shares issued | — | — | — | — | — | — | — | 1.8*+780%— | 0.0*—— | — | — | 0.2*—— | 0*—0.0% | |
| Cash from financing activities | 21−61.9%— | 9.7*+857%56912% | −0.1—−738% | 11*−78.5%— | 0.1*−94.9%— | 1.0*—— | −0.4—— | 51*+9125%— | 2.4*—— | 0*—— | 0—— | 0.6*—— | −0.0*—−6.8% | |
| Change in cash | −17−402%— | −4.6*—−26906% | −7.5—−46781% | 4.2*−89.0%— | −9.3*—— | −12*—— | −14—— | 38*—— | −5.4*−193%— | −8.3*—— | −12—— | −6.4*—— | 5.7*—1698% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Senti Biosciences, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$0 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Senti Biosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 10 · Agreement ended 1 · New debt 4 · Unregistered share sale 3 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedMaterial agreementAgreement endedUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K | |
| Delisting noticeMaterial agreement | 8-K | |
| Material agreementNew debt | 8-K | |
| Change in controlMaterial agreementResults announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Change in controlMaterial agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2024 | $38 M | Private placement after listing | $10 to $50 million | 15 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Senti Biosciences, Inc.#
6 labor condition applications certified in fiscal 2024 for 6 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist IIBiochemists and Biophysicists | 1 | — |
| Senior Research Associate I, PreClinical ResearchMolecular and Cellular Biologists | 1 | $102 K |
| Senior Research Associate I, Process ScienceMolecular and Cellular Biologists | 1 | $102 K |
| Senior ScientistBioinformatics Scientists | 1 | $120 K |
| Senior Scientist I, Gene Circuit Discovery (HTS)Biochemists and Biophysicists | 1 | $145 K |
| Senior Scientist II, Process DevelopmentBiochemists and Biophysicists | 1 | $175 K |
Where: South San Francisco, CA 6
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2024 | 6 | 6 | $120 K | 6 |
| FY2023 | 7 | 7 | $129 K | 7 |
| FY2022 | 2 | 2 | $128 K | 2 |
| FY2021 | 1 | 1 | $129 K | 1 |
| FY2020 | 3 | 3 | $83 K | 3 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Senti Biosciences, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 37% of workforce | Restructuring planSEC 8-K | “Pursuant to these plans, the Company is reducing its workforce by approximately 37%.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Senti Biosciences, Inc. compares in Biotechnology
- Market cap$19 M · higher than 17% of 726
- Revenue$0 M · higher than 13% of 647
- Price / sales943.0× · lower than 0% of 339
- Price / book3.4× · lower than 44% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Senti Biosciences, Inc.🇺🇸 | $19 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 19, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Senti Biosciences, Inc.? Verify and update this profile — free
Show Senti Biosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.